Y-mabs announces submission of naxitamab biologics license application to u.s. fda

Y-mabs announces submission of naxitamab biologics license application to u.s. fda.y-mabs therapeutics, - has completed submission of biologics license application for naxitamab after market close on march 31.

YMAB Ratings Summary

YMAB Quant Ranking